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Idiopathic pulmonary fibrosis is a very common interstitial lung disease derived from 
chronic inflammatory insults, characterized by massive scar tissue deposition that 
causes the progressive loss of lung function and subsequent death for respiratory failure. 
Bleomycin is used as the standard agent to induce experimental pulmonary fibrosis in 
animal models for the study of its pathogenesis. However, to visualize the establishment 
of lung fibrosis after treatment, the animal sacrifice is necessary. Thus, the aim of this 
study was to avoid this limitation by using an innovative approach based on a double 
bleomycin treatment protocol, along with the in  vivo images analysis of bleomycin-
treated mice. A reporter gene construct, containing the luciferase open reading frame 
under the matrix metalloproteinase-1 promoter control region, was tested on double 
bleomycin-treated mice to investigate, in real time, the correlation between bleomycin 
treatment, inflammation, tissue remodeling and fibrosis. Bioluminescence emitted by the 
lungs of bleomycin-treated mice, corroborated by fluorescent molecular tomography, 
successfully allowed real time monitoring of fibrosis establishment. The reporter gene 
technology experienced in this work could represent an advanced functional approach 
for real time non-invasive assessment of disease evolution during therapy, in a reliable 
and translational living animal model.
Keywords: idiopathic pulmonary fibrosis, bleomycin, matrix metalloproteinase-1 promoter, bioluminescence, 
fluorescent molecular tomography
inTrODUcTiOn
Idiopathic pulmonary fibrosis (IPF), the most common of the idiopathic interstitial pneumonias, 
is a devastating condition that carries a prognosis worse than that of many cancers. The median 
survival of patients with well-defined IPF is less than 5  years after diagnosis (1, 2). Fibrosis, 
in general, is defined by the excessive accumulation of fibrous connective tissue (components 
Abbreviations: IPF, idiopathic pulmonary fibrosis; MMP-1, matrix metalloproteinase-1; ELISA, enzyme-linked immu-
nosorbent assay; ORF, open reading frame; FMT, fluorescent molecular tomography; BLI, bioluminescence imaging; 
BALF, bronchoalveolar lavage fluid; HBSS, Hank’s balanced salt solution; EDTA, ethylenediaminetetraacetic acid; HEPES, 
4-(2-hydroxy-ethyl)-1-piperazineethansulphonic acid; FBS, fetal bovine serum.
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of the extracellular matrix such as collagen and fibronectin) 
in and around inflamed or damaged tissue, which can lead to 
permanent scarring, organ malfunction, and, ultimately, death, 
as is the case for IPF.
A better understanding of the pathogenesis of IPF is 
critical for the identification of new therapeutic targets as well 
as molecules that may serve as surrogate markers for clinically 
significant endpoints. During the last 20  years, the knowledge 
regarding the pathogenesis of pulmonary fibrosis has substan-
tially improved, and potential targets for novel therapies have 
been identified. In contrast, despite many potentially effective 
anti-fibrotic therapeutics have been generated, only few of them 
accomplished their translation in clinical application. The in vivo 
study, to recapitulate the pathogenesis, the disease phenotype as 
well as the effect of a drug on the disease outcome, represents the 
main obstacle to be overcome during the last steps of develop-
ment of such compounds. Different models have been built over 
time to examine pulmonary fibrosis. These methods include 
radiation damage, administration of asbestos and silica, and 
administration of fibrinogenic cytokines and bleomycin (3). This 
later method became the standard agent to induce experimental 
pulmonary fibrosis in animals such as small laboratory animals 
(including mice, rats, guinea pigs, hamsters, and rabbits) (3, 4) 
and large animals (including non-human primates, horses, dogs, 
and ruminants) (3, 5, 6). Bleomycin was initially discovered as 
chemotherapeutic antibiotic made by the bacterium Streptomyces 
verticillus (7), and it is still used for some forms of neoplasia (8). 
Its use in animal models of pulmonary fibrosis is based on the 
fact that fibrosis is a side effect of this agent in human cancer 
therapy (8).
As in all the models focused on modeling a chronic pulmo-
nary fibrotic state in animals, fibrotic lesions occur 2–3 weeks 
after bleomycin injury. The time needed to develop these 
lesions coupled with the necessity to investigate drug effects 
after interventional treatment on established fibrosis to dissect 
the anti-fibrotic effects from anti-inflammatory and radical 
scavenging activities make the bleomycin model a very time 
consuming one. Moreover, for the detection and quantifica-
tion of bleomycin-induced lung damage/injury most of the 
analysis routinely performed, including biochemical measures 
of matrix deposition and morphometrical and histological 
analysis, were based on animal sacrifice for postmortem 
analysis, thus preventing the reuse of the animal for further 
investigation.
Although other imaging technologies have been used to 
follow the establishment of lung fibrosis in real time, such as 
micro-CT, PET, MRI, and cathepsin-activated fluorescent 
probes (9–11), we propose an innovative and easy in vivo biolu-
minescent imaging (BLI) approach for drug discovery purpose.
MaTerials anD MeThODs
reagents
In vivo JetPEI DNA transfection reagent (Polyplus Transfection) 
was obtained from Euroclone (Milan, Italy), and d-luciferin was 
obtained from Perkin Elmer Inc. (Boston, MA, USA). Bleomycin 
sulfate from S. verticillus (Sigma B2434).
experimental animals
Female inbred C57Bl/6 (7- to 8-week old) mice were purchased 
from Harlan Laboratories Italy (San Pietro al Natisone, Udine, 
Italy). Prior to use, animals were acclimatized for at least 5 days 
to the local vivarium conditions (room temperature: 20–24°C; 
relative humidity: 40–70%; 12-h light–dark cycle), having free 
access to standard rodent chow and softened tap water. All animal 
experiments described herein were approved by the intramural 
animal-welfare committee for animal experimentation of Chiesi 
Farmaceutici and comply with the European Directive 2010/63 
UE, Italian D.Lgs 26/2014 and the revised “Guide for the Care and 
Use of Laboratory Animals.”
In Vivo gene Delivery
The pMMP-1-Luc was obtained by subcloning a 1101 MluI/XhoI 
bMMP-1 promoter sequence, digested with the same enzymes 
from pEX-A2 (Eurofins) and inserted in Mlu/XhoI digested 
pGL3 basic vector (Promega). We applied in vivo JetPEI (Polyplus 
Transfection) as a carrier for delivering DNA to lung tissues. The 
DNA and JetPEI mix was formulated according to the product 
manual with a final N/P ratio of 7. Briefly, 50 μg of bMMP-1-luc 
and 7 μl of JetPEI were both diluted into 200 μl 5% glucose. The 
two solutions were then mixed and incubated for 15 min at room 
temperature. The entire mixture was injected intravenously into 
C57Bl/6 mice, and the expression of pbMMP-1-Luc was moni-
tored through imaging with an IVIS imaging system.
In Vivo Bioluminescence imaging
Transfection per  se causes a mild lung inflammatory response 
and matrix metalloproteinases (MMPs)-1Luc activation that 
is detectable by BLI up to 3–4  days after DNA injection and 
disappears completely after 1  week (12, 13). One week after 
DNA delivery, the transient transgenic mice were injected 
intraperitoneally (i.p.) with luciferin (150 mg/kg), and BLI was 
recorded in order to check the baseline activation of the MMP-1 
pathway. Briefly, 10 and 15  min following luciferin injection, 
mice were lightly anesthetized with isoflurane (2.5% in oxygen), 
and images were obtained using the IVIS imaging system: a total 
of photons emitted from the chest of the mice was quantified 
using Living Image® software (Perkin Elmer Inc., Boston, MA, 
USA). The following day, mice were intratracheally challenged 
with bleomycin or with saline, and BLI was recorded at 4, 24, 
48 h, and every 7 days for 3 weeks. Data were expressed as mean 
folds of induction (FOI) over the baseline activation of each 
mouse (12, 14, 15).
In Vivo Fluorescent Molecular Tomography 
(FMT) imaging
Bleomycin-treated and control mice were injected intravenously 
with MMPSense680 (Perkin Elmer Inc., Boston, MA, USA) at 
80 nmol/kg at 7, 14, and 21 days and imaged 24 h after probe 
injection. MMPSense680 is a metalloproteinase activatable 
fluorescent in vivo imaging agent that is activated by key MMPs 
including MMP-2, -3, -9, and -13. MMPSense 680 is optically 
silent in its inactivated state and becomes highly fluorescent fol-
lowing metalloprotease-mediated activation (13, 16).
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Mice were anesthetized using isoflurane (2.5% in oxygen) and 
depilated to minimize fur interference with fluorescent signal. 
Depilatory cream was applied thickly on skin over the upper 
torso (front, back, and sides) of each mouse, rinsed off with warm 
water, and reapplied until all fur had been removed.
Bleomycin-challenged and control mice were then imaged 
using the FMT 2500 in  vivo imaging system (Perkin Elmer 
Inc., Boston, MA, USA). Briefly, the anesthetized mice were 
carefully positioned in the imaging cassette, which was then 
placed into the FMT imaging chamber. A near infrared (NIR) 
laser diode transilluminated (i.e., passed light through the body 
of the animal to be collected on the opposite side) the thorax 
region, with signal detection occurring via a thermoelectrically 
cooled charge-coupled device camera placed on the opposite 
side of the imaged animal. Appropriate optical filters allowed 
collection of both fluorescence and excitation data sets, and 
the multiple source-detector fluorescence projections were 
normalized to the paired collection of laser excitation data. The 
entire image acquisition sequence took approximately 4–5 min 
per mouse.
The collected fluorescence data were reconstructed by FMT 
2500 system with TrueQuant software version 2.2 (Perkin Elmer 
Inc., Boston, MA, USA) for the quantification of three-dimen-
sional fluorescence signal within the lungs. The total amount of 
lung fluorescence (in picomoles) was automatically calculated 
from internal standards generated with known concentrations of 
appropriate NIR dyes.
Bleomycin administration
For intratracheal administrations, 50  μl/mouse either saline 
or bleomycin (1  mg/kg) were given directly through the tra-
cheal cannula instillation under isoflurane (2.5% in oxygen) 
anesthesia, using a small laryngoscope (Penn-Century Inc., 
Philadelphia, PA, USA) to visualize the trachea. In brief, mice 
were anesthetized and challenged intratracheally with saline, or 
with bleomycin single dose at day 0 or bleomycin double treat-
ment at day 0 and day 4.
Bronchoalveolar lavage, cytokines, 
and MMPs
At days 7, 14, and 21  days posttreatment the first bleomycin 
challenge, animals were anesthetized with isoflurane and sac-
rificed by bleeding from the abdominal aorta. Bronchoalveolar 
lavage fluid (BALF) was collected by gently washing the lungs 
with 0.6 mL sterile solution [Hank’s balanced salt solution × 10; 
ethylenediaminetetraacetic acid 100  mM; 4-(2-hydroxy-ethyl)-
1-piperazineethansulphonic acid 1 mM; and distilled water] for 
three times in the bronchial tree and collected for subsequent 
analysis (14). After centrifugation at 400 g for 10 min, the BAL 
supernatants were frozen at −80°C for simultaneous quantitation 
of multiple cytokines/chemokines using a Bio-Plex™ Cytokine 
Assay Kit (Bio-Rad Laboratories, Segrate, Milano, Italy). The 
cell pellet was resuspended in 0.2 ml of PBS. Cell number was 
counted with an automated cell counter (Dasit XT 1800J). The 
concentration of MMP proteins in BAL fluid was determined 
by enzyme-linked immunosorbent assay (ELISA). MMP-2, 
MMP-9, and TIMP-1 were measured with specific ELISA kit 
(R&D System), and MMP-1 was measured with Mouse Matrix 
Metalloproteinase 1 ELISA Kit (MyBioSource) according to the 
manufacturer’s instructions.
histology
Lungs were removed and inflated with a cannula through the 
trachea by gentle infusion with 0.6 ml of 10% neutral-buffered 
formalin. After the lungs were placed in a vial containing 10% 
formalin and fixed for at least 24 h. For the histology, the whole 
lungs were dehydrated in graded ethanol series, clarified in xylene 
and paraffin embedded. Sections of 5 μm thick were cut with a 
rotary microtome (Reichert-Jung 1150/Autocut) in ventral dorsal 
plane. Fibrotic lesions were assessed morphologically and semi-
quantitatively graded according to the scale defined by Ashcroft 
and modified by Hübner et al. (17). Three sections for each lung 
sample were stained with Masson’s Trichrome, and tissue dam-
age was assessed by a system of 0–8 score. For each section, all 
the tissue was scored as independent microscopic fields at 20×, 
where the degree of fibrosis was recorded as that occupying more 
than half of each field. The final score was expressed as a mean of 
individual scores observed on all microscopic fields and sections 
at the magnification of 20×.
Data analysis
Data were expressed as the mean and SEM of the mean of n ani-
mals. Statistical analysis was performed using (PRISM Statistical 
software v 4.0.3). Changes were compared to the vehicle groups 
using ANOVA followed by Dunnett’s test. *p < 0.05; **p < 0.01 
and #p < 0.05; ##p < 0.01 when changes were compared to each 
group vs every other group using ANOVA followed by Tukey’s 
multiple comparison test.
resUlTs anD DiscUssiOn
To better understand the pathogenesis of lung fibrotic disorders, 
different models of pulmonary fibrosis have been developed 
over the years. Most of them mimic some, but never all features 
of human IPF, especially the progressive and irreversible nature 
of the condition. Among currently applied models of experi-
mentally induced pulmonary fibrosis, the administration of 
bleomycin is used most frequently. Moreover, the bleomycin-
induced lung fibrosis animal model has emerged as the best 
characterized to study IPF disease although this murine model 
has its own strengths and weaknesses. Bleomycin-induced 
pulmonary fibrosis is often unpredictable, indeed different 
factors will affect the nature of the fibrotic response, including 
the route of administration, preparation, dose, strain, and age 
of mice (18). Thus, the first objective of the present work was to 
attempt a different bleomycin-induced lung fibrosis protocols by 
comparing a single and a double dose of bleomycin intratracheal 
instillation. The second objective of this work is to monitor lung 
fibrosis through non-invasive BLI technique using the pulmo-
nary fibrosis mouse model established in this study.
Bleomycin was intratracheally administered as a single 
(at day 0; 1 mg/kg of bleomycin in 50 μl) or as a double dose 
(at day 0 and day 4; 1 mg/kg of bleomycin in 50 μl). Two groups 
FigUre 1 | (a) Quantification of collagen deposition in the lung of intratracheally instilled with a single (bleomycin once) or double (bleomycin twice) dose of 
bleomycin and compared with single (saline once) or double (saline twice) dose vehicle (saline) treated mice at 7, 14, and 21 days posttreatment. (B) Ashcroft 
frequency distribution of single (bleomycin once) or double (bleomycin twice) dose of bleomycin and compared with double dose vehicle (saline) treated mice at 7, 
14, and 21 days posttreatment. The total Ashcroft score has been divided in three classes (1–3, mild; 4, moderate; ≥5, severe fibrosis). (c) Representative images 
of mouse lung sections treated and untreated with bleomycin and used for the above of the quantification (10×; scale bar is equal to 100 μm). Nine animals were 
used for each time point, and each time point was repeated three times. The data represent the mean ± SEM of a total of 27 animals. Changes were compared to 
the vehicle groups using ANOVA followed by Dunnett’s test. *p < 0.05; **p < 0.01 and #p < 0.05; ##p < 0.01 when changes were compared to each group vs every 
other group using ANOVA followed by Tukey’s multiple comparison test.
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of mice (n =  12) intratracheally instilled with only vehicle at 
the same time and volume used for the groups of test mice were 
used as untreated controls. Bleomycin- and vehicle-treated 
mice were daily visually monitored for adverse reactions 
potentially induced by the treatment and weekly weighed for 
the complete duration of the experimental period. The majority 
of side effects were reported in the bleomycin double-treated 
mice that showed a body weight reduction associate with 10% 
of mortality from 9 to 15 days after bleomycin administration. 
No weight loss was found in the control group (Figure S1 in 
Supplementary Material).
For the assessment of fibrosis, a semiquantitative histological 
analysis was performed based on the scoring system by Ashcroft. 
Single intratracheal administration revealed high variability 
intra-experiment; the fibrosis lesions detected by histological 
analysis were not very severe (Figures 1A–C) and increasing the 
dose of single bleomycin instillation resulted only in an increased 
toxicity and mortality (data not shown).
In the single bleomycin-treated group, moderate structural 
changes were observed at 14 days and tend to resolve spontane-
ously up to 3 weeks (Figures 1A,B). Histology pictures showed 
the formation of only single fibrotic masses (Figure  1C). The 
tendency of spontaneous resolution of the lung fibrosis in single 
treated group represents a real limitation for pharmacological 
intervention due to restrict therapeutic window allowing only 
preventing treatment that does not mimic the clinical practice. 
On the contrary, in the double bleomycin-treated group, histol-
ogy analysis revealed more severe pattern of fibrosis started from 
day 7, mainly as single fibrotic masses, and evolved at days 14 
as confluent conglomerates of substitutive collagen and remain 
stable till day 21 (Figures 1A–C).
Starting from the assumption that bleomycin is a lung 
pro-inflammatory molecule and white blood cells (WBC) 
should be recruited in an inflamed tissue, WBC content in 
the BALF of bleomycin-treated mice was compared with 
those treated with vehicle. As expected WBC in BALF of 
bleomycin-treated mice, as monitored at days 7, 14, and 21, 
was strongly higher (1.09 ±  0.12 ×  103  cell/μl for single treat-
ment and 1.18 ±  0.19 ×  103  cell/μl or double treatment) than 
in the vehicle treated groups (0.2 ±  0.05 ×  103  cell/μl), but no 
differences between single and double treatment were observed 
(Figure  2A). Interestingly, lymphocyte fraction in the double-
treated group increased at day 21 (Figure  2C); macrophage 
fraction increased at each time of treatment and remained high 
FigUre 2 | cellular infiltration into the bronchoalveolar lavage fluid (BalF) of mice lung intratracheally instilled with a single (bleomycin once) or 
double (bleomycin twice) dose of bleomycin and compared with single (bleomycin once) or double (bleomycin twice) dose vehicle (saline) treated 
control groups. Cellular infiltration was detected at 7, 14, and 21 days posttreatment. The amount of white blood cells (WBC) (a), macrophages (B), lymphocytes 
(c), neutrophils (D), and monocytes found in BALF was expressed as number of cells per microliter. Nine animals were used for each time point, and each time 
point was repeated three times. The data represent the mean ± SEM of a total of 27 animals. Changes were compared to the vehicle groups using ANOVA followed 
by Dunnett’s test. *p < 0.05; **p < 0.01 and #p < 0.05; ##p < 0.01 when changes were compared to each group vs every other group using ANOVA followed by 
Tukey’s multiple comparison test.
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mainly in double-treated group (Figure  2B); in contrast, no 
significant increase of the neutrophil fraction was observed in 
single bleomycin-treated mice. Whereas for bleomycin double 
treated mice, a significant increase at day 7 was observed 
(Figure  2D). Therefore, double administration of bleomycin 
increase, in general, WBC infiltration into the lung.
To correlate WBC infiltration and inflammation, a set of 
cytokines and chemokines [chemokine (C–X–C motif) ligand 1 
(CXCL1 also KC), granulocyte colony-stimulating factor, inter-
leukin 10, chemokine (C–C motif) ligand 5 (CCL5 also RANTES), 
and interleukin-12 subunit p40] were estimated by cytokine 
multiplex assay in the BALF. Indeed, all cytokines/chemokines 
estimated significantly increased in bleomycin double-treated 
mice with respect to the single bleomycin-treated mice and the 
untreated controls (Figure  3). The inflammatory response to 
double bleomycin treatment was further corroborated by the 
presence of MMP-1 (Figure 4A), MMP-2 (Figure 4B), MMP-9 
(Figure 4C), and their inhibitor, TIMP-1 proteins (Figure 4D) 
by ELISA in the BALFs. All the data described above were sat-
isfactorily in agreement with the increase of collagen deposition 
and maintenance in double treatment with bleomycin. The cor-
relation between bleomycin double treatment, WBC infiltration, 
cytokine expression, MMP expression, and collagen deposition 
prompted us on the potential use of MMP gene as a marker for an 
in vivo real time monitoring of bleomycin-induced lung fibrosis. 
After an accurate comparison between single vs double bleomy-
cin administration, we decided to use only the double protocol 
instillation for further experiments.
For translating the experimental setting to a different animal 
species different than mouse, it was decided to use heterologous 
DNA sequences coming from the bovine MMP-1 gene (“Bos_tau-
rus.UMD3.1.68” reference genome). A reporter gene construct 
containing a 1,089  bp minimal MMP-1 promoter sequence 
including the putative TATAbox and most of the 5′-UTR was 
cloned in front of the firefly luciferase gene contained in the pGL3 
basic vector to generate pbMMP-1-Luc (19).
The possibility to monitor longitudinally in non-invasive way, 
the activation of MMP-1 in the same mice is step a forward in 
investigating the molecular mechanism linked to fibrosis progres-
sion, with the advantage of reducing variability intra-experiments 
and the number of animals required.
The gene delivery technology has extensively been used in our 
lab, and we know that the transient transgene expression could 
last for more the 60  days (14), starting from this assumption, 
mice were transiently transgenized with pbMMP-1-Luc. The 
DNA, when is systemically administered, is able to transfect the 
50% of epithelial and endothelial cells in the lung (13). One week 
post-transgenization, all the mice were first imaged to detect a 
residual BLI signal (12, 13), and, at the same time, they were 
intratracheally instilled with bleomycin. At day 4, bleomycin 
was given for the second time to all the mice. At different time 
points (7, 14, and 21  days) after bleomycin treatment, mice 
were monitored for BLI expression and MMPS activation in 
the lung by IVIS and FMT in vivo imaging. In vivo and ex vivo 
BLI images (Figures  5A–D) showed that mice responded to 
bleomycin insult with a maximal signal at 14 days. In contrast, 
no signal was observed for control mice treated with saline or 
those transiently transgenized with the empty vector (data not 
shown). The difference in term of time between MMP-1 detected 
into the BALF and MMP-1 promoter activation measured by 
FigUre 3 | cytokines/chemokines (a) g-csF; (B) ranTes; (c) il 12p40; (D) Kc; (e) il 10, determination into the bronchoalveolar lavage fluid of mice 
lung intratracheally instilled with a single (bleomycin once) or double (bleomycin twice) dose of bleomycin and compared with single (bleomycin 
once) or double (bleomycin twice) dose of vehicle (saline) treated control groups. Determination was made at 7, 14, and 21 days posttreatment. Nine 
animals were used for each time point, and each time point was repeated three times. The data represent the mean ± SEM of a total of 27 animals. Changes were 
compared to the vehicle groups using ANOVA followed by Dunnett’s test. *p < 0.05; **p < 0.01 and #p < 0.05; ##p < 0.01 when changes were compared to each 
group vs every other group using ANOVA followed by Tukey’s multiple comparison test.
FigUre 4 | Matrix metalloproteinase-1 (MMP-1) (a), MMP-2 (B), MMP-9 (c), and TiMP-1 (D) expression into the mice lung bronchoalveolar lavage 
fluid, intratracheally instilled with double (bleomycin twice) dose of bleomycin and compared with vehicle (saline) treated control mice groups. 
MMP-1, MMP-2, MMP-9, and TIMP-1 expression was detected at 7, 14, and 21 days posttreatment. Nine animals were used for each time point, and each time 
point was repeated three times. The data represent the mean ± SEM of a total of 27 animals. Changes were compared to the vehicle groups using ANOVA followed 
by Dunnett’s test. *p < 0.05; **p < 0.01.
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BLI could be explained by the fact that MMP transcription 
takes place early respect to lung tissue chronic inflammation 
and tissue modification, which need longer time.
Signal intensity was then expressed as FOI where the saline-
treated control was considered as 1 (Figure 5E). A further control 
was established with mice transiently transgenized with STAT-1-
Luc vector because STAT-1 is not controlled by transcription but 
by its activation through phosphorylation upon the interaction 
with JAK, in fact no signal was detected after bleomycin treat-
ment (Figure S2 in Supplementary Material).
This in  vivo bioluminescent analysis demonstrated the 
specificity of the system even using a promoter coming from 
a different animal species. The role of MMPs in the present 
bleomycin double treatment protocol was further corroborated 
by using the FMT imaging technology, injecting the mice with 
MMPSense 680 at different time points (7, 14, and 21 days). In 
fact, bleomycin-treated mice were found to be responsive in 
terms of lung MMP protein expression as revealed by the acti-
vation of MMP-specific fluorescent probes (Figure 6). In vivo 
and ex vivo time course results were reported as mean ± SEM 
and significance attributed when *p < 0.05 or **p < 0.01. These 
results underlines the possible use of two molecular readouts 
in the same animal in  vivo, which represents a step ahead 
toward the understanding of a very complex disease such as 
IPF and other diseases involving MMP activation and collagen 
deposition.
FigUre 5 | In vivo (a,B) and ex vivo (c,D) representative images of pbMMP-1-luc transiently transgenized mice treated with saline (a,c) or 
bleomycin (B,D) at different time posttreatment (7, 14, and 21 days posttreatment). Mice were monitored before the treatment to get the baseline and at 4, 
24, and 48 h posttreatment by in vivo image analysis drawing a region of interest over the chest and using an IVIS imaging system (Perkin Elmer Inc., Boston, MA, 
USA). Light emitted was acquired from specific regions by Living Image® software (Perkin Elmer Inc., Boston, MA, USA) as photon per second per square 
centimeter and normalized as folds of induction respect to the saline-treated control (e). Statistical differences were tested by one-way ANOVA followed by 
Dunnett’s post hoc test for group comparisons. Nine animals were used for each time point, and each time point was repeated three times. The data represent the 
mean ± SEM of a total of 27 animals. Changes were compared to the vehicle groups using ANOVA followed by Dunnett’s test. *p < 0.05; **p < 0.01.
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Herein, attempting to correlate bleomycin-induced lung 
inflammation, tissue damage and remodeling processes, 
several MMPs and their inhibitor, such as TIMP-1, in double 
bleomycin-treated mice were found expressed. Although MMP-2 
and MMP-9 were better upregulated respect to MMP-1 in our 
experimental setting, it was of greater significance focusing on 
MMP-1 for several reasons. The molecular events involving IPF 
in lethal lung disorders, such us pulmonary fibrosis and including 
bleomycin-induced fibrosis, have not been completely elucidated; 
fibrinogenic pathway activation, along with the recruitments of 
epithelial cells to epithelial–mesenchymal transition phenom-
ena, seem to have a pivotal role, and MMP-1 is one of the most 
expressed gene (20–23). MMP-1 is an archetypical collagenase, 
whose substrates were represented by collagenase type I, II, and/
or III. Further, several investigations have demonstrated that 
MMP-1 plays an activating role in detaching membrane-linked 
form of several precursor molecules from the cell surface. After 
MMP-1 cleavage, the biologically active forms of these molecules 
can freely diffuse and act into the tissue interstitial space or be 
transported by the blood or lymphatic stream to distant differ-
ent places from where they have been produced. Among these 
precursor molecules, pro-TGF-α, EGF-like ligands, and TGF-β 
precursor can be listed. MMP-1 has also been proven to process 
different important mediators, such as pro-TNF-α, pro-IL-1β, 
L-selectin, α1-antitripsin inhibitor, connective tissue growth fac-
tor, complement C1q fraction, IL-8, and growth factor-binding 
proteins 1 and 3 (24–27). Regarding IL-8, it is important to note 
that the MMP-cleaved form of this cytokine is 10-fold more 
potent than the original molecule (28). Indeed, the overexpres-
sion of MMP-1 was detected in lung of cigarettes smoking people, 
FigUre 6 | In vivo (a,B) and ex vivo (c,D) fluorescent molecular tomography (FMT) representative images of mice injected with MMPsense 680 
treated with saline or double treated with bleomycin at different time posttreatment (7, 14, and 21 days). The total amount of lung fluorescence signal was 
automatically calculated by FMT with True Quant software version 2.2 (Perkin Elmer Inc., Boston, MA, USA). (e) Nine animals were used for each time point, and 
each time point was repeated three times. The data represent the mean ± SEM of a total of 27 animals. Changes were compared to the vehicle groups using 
ANOVA followed by Dunnett’s test. *p < 0.05; **p < 0.01.
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people with lung emphysema, with IPF and cancer (29, 30). An 
important feature for MMP-1 pathway investigation is the identi-
fication of a suitable laboratory animal model where MMP-1 gene 
expression can be easily detected, following a specific stimulus, 
and manipulated. Human MMP-1 gene and protein are highly 
conserved among different animal species in terms of structure 
and function, in fact human MMP-1 has more than 99% of 
identity with Bos taurus and Capra hircus (31, 32). Recently, two 
genes with similar characteristics of human and bovine MMP-1, 
Mmp1a and Mmp1b, have been identified in mice. These two 
genes have 82% of similarity while Mmp1a has 58% of similarity 
with human MMP-1, as well as a similar chromosomal location 
and surrounding genes, such as MMP-3 and MMP-10, as revealed 
by chromosome mapping (31–33),. For these reasons and for its 
collagenase activity, absent in Mmp1b, Mmp1a was considered 
the natural mouse ortholog of human and bovine MMP-1. Taking 
advantage from the data previously obtained from the use of a 
bovine IL-8 luciferase reporter construct, which was successfully 
employed to transiently transgenize mice, even though mice 
do not bear a functional IL-8 gene (12, 14, 15), a new reporter 
construct was generated. Moreover, in different experimental set-
tings using human regulatory sequences for in vivo gene delivery 
in rodents, for reasons we still do not understand, we noticed 
that bovine sequences seem to be better recognized by the mouse 
transcriptional apparatus than the human one. For this reason, it 
was decided to use the bovine MMP-1 promoter than the human 
ones, and this model could be of great value for drug discovery in 
human lung diseases.
The proximal promoter of the bovine MMP-1 gene was used 
to drive the luciferase reporter gene transcription, transiently 
transgenized mice were generated, intratracheally double treated 
with bleomycin and luminescence signal intensity monitored at 
different time points. By this experimental setting, mouse cell 
signaling and transcriptional apparatus were able to recognize 
the bovine MMP-1 promoter following the specific fibrotic insult 
induced by bleomycin treatment. This has allowed us to develop 
a more reproducible and robust murine model for lung fibrosis 
based on a double intratracheal administration of bleomycin, 
and also opened up a new door for in vivo monitoring in real 
time by BLI a specific molecular mechanism linked to pulmo-
nary fibrosis.
The simple system applied for the generation of transient 
transgenic mice resulted to be a valid alternative to the normal 
transgenesis. The utility of reporter gene technology makes possi-
ble to analyze specific cellular and biological processes in a living 
animal through in  vivo imaging methods. BLI from luciferase 
gene expression, as is the case of the reporter construct employed 
during this study, is the most widely used. Because mammalian 
tissues do not naturally emit bioluminescence, in  vivo BLI has 
considerable appeal because images can be generated with 
absence of background signal. BLI requires an expression cas-
sette consisting of the bioluminescence reporter gene (in this 
case was luciferase) under the control of a selected promoter (in 
this experimental setting the B. taurus gene promoter) driving 
the reporter. In order to induce light production, the substrate 
luciferin must be provided by intravascular or intraperitoneal 
injection. To date, there have been no reports of toxicity related 
to repeated dosing of substrates (34), and bMMP-1-luciferase 
transiently transgenized mice could be reutilized.
Thus, the capability to monitor a biological process longi-
tudinally in the same mouse represents an obvious advance 
for functional as well as pharmacological studies. Although 
FMT detected a better signal respect to BLI, BLI is more com-
monly used, versatile, inexpensive, and handy for either drug 
discovery or basic science. The major drawback for FMT is the 
dependencies from the commercial probes, which can be very 
expensive, require continue administration, and need high-skill 
operators to be reproducible. BLI, through specific promoters 
driving a reporter gene, is targeting the transcriptional control 
of a specific molecule, whereas FMT is targeting the activation 
of proteins, in this specific case the proteases already present 
in the diseased tissue. Therefore, the two technologies are not 
completely overlapping, and in our case, the use of FMT was to 
further validate BLI.
The correlation between bleomycin treatment, lung inflamma-
tion, MMP upregulation and collagen deposition is in accordance 
with the recognized MMP role as a key factor in orchestrating the 
onset of lung fibrosis, thus further validating the model presented 
by this work, which is suitable to functional and pharmacologi-
cal study in a convenient small size experimental animal model 
aimed to combat a devastating disease such as pulmonary fibrosis 
and other diseases related to it.
eThics sTaTeMenT
Animal experiments were conducted in compliance with 
national (Decreto Legislativo numero 26, 4 Marzo 2014) and 
international laws and policies (Guide for the Care and Use 
of Laboratory Animals). Animal studies were approved by 
the Institutional Animal Care and Use Committee at Chiesi 
Farmaceutici, Parma, Italy.
aUThOr cOnTriBUTiOns
FS and GD conceived the experiments. FS, FRuscitti, DP, 
FRavanetti, GT, FM, AV, GV, and GD performed the experiments. 
GD and FS analyzed the data. GD wrote the paper.
acKnOWleDgMenTs
The authors would like to thank Dr. Laura Kramer for the English 
editing of the manuscript.
FUnDing
This work was supported by Italian Ministry of University and 
Scientific Research (Italian National Grant MIUR, PRIN 2010-
2011) and internal funds of Chiesi Farmaceutici, srl Parma, Italy.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found 
online at http://journal.frontiersin.org/article/10.3389/fimmu. 
2017.00199/full#supplementary-material.
10
Stellari et al. Real-time Monitoring of Lung Fibrosis
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 199
reFerences
1. Demedts M, Costabel U. ATS/ERS international multidisciplinary consensus 
classification of the idiopathic interstitial pneumonias. Eur Respir J (2002) 
19(5):794–6. doi:10.1183/09031936.02.00492002 
2. Cottin V, Capron F, Grenier P, Cordier JF. [Diffuse idiopathic interstitial 
pneumonias. International multidisciplinary consensus classification by the 
American Thoracic Society and the European Respiratory Society, principal 
clinico-pathological entities, and diagnosis]. Rev Mal Respir (2004) 21(2 Pt 
1):299–318. doi:10.1016/S0761-8425(04)71288-7 
3. Moore BB, Lawson WE, Oury TD, Sisson TH, Raghavendran K, Hogaboam 
CM. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol (2013) 
49(2):167–79. doi:10.1165/rcmb.2013-0094TR 
4. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am 
J Physiol Lung Cell Mol Physiol (2008) 294(2):L152–60. doi:10.1152/
ajplung.00313.2007 
5. Organ L, Bacci B, Koumoundouros E, Barcham G, Kimpton W, Nowell CJ, 
et al. A novel segmental challenge model for bleomycin-induced pulmonary 
fibrosis in sheep. Exp Lung Res (2015) 41(3):115–34. doi:10.3109/0190214
8.2014.985806 
6. Organ L, Bacci B, Koumoundouros E, Barcham G, Milne M, Kimpton 
W, et  al. Structural and functional correlations in a large animal model 
of bleomycin-induced pulmonary fibrosis. BMC Pulm Med (2015) 15:81. 
doi:10.1186/s12890-015-0071-6 
7. Shen B, Du L, Sanchez C, Edwards DJ, Chen M, Murrell JM. Cloning 
and characterization of the bleomycin biosynthetic gene cluster from 
Streptomyces verticillus ATCC15003. J Nat Prod (2002) 65(3):422–31. 
doi:10.1021/np010550q 
8. Yu Z, Yan B, Gao L, Dong C, Zhong J, D Ortenzio M, et al. Targeted delivery 
of bleomycin: a comprehensive anticancer review. Curr Cancer Drug Targets 
(2016) 16(6):509–21. doi:10.2174/1568009616666151130213910 
9. Tassali N, Bianchi A, Lux F, Raffard G, Sanchez S, Tillement O, et  al. 
MR imaging, targeting and characterization of pulmonary fibrosis 
using intra-tracheal administration of gadolinium-based nanoparti-
cles. Contrast Media Mol Imaging (2016) 11(5):396–404. doi:10.1002/ 
cmmi.1703 
10. Vande Velde G, Poelmans J, De Langhe E, Hillen A, Vanoirbeek J, 
Himmelreich U, et al. Longitudinal micro-CT provides biomarkers of lung 
disease that can be used to assess the effect of therapy in preclinical mouse 
models, and reveal compensatory changes in lung volume. Dis Model Mech 
(2016) 9(1):91–8. doi:10.1242/dmm.020321 
11. Withana NP, Ma X, McGuire HM, Verdoes M, van der Linden WA, Ofori LO, 
et al. Non-invasive imaging of idiopathic pulmonary fibrosis using cathepsin 
protease probes. Sci Rep (2016) 6:19755. doi:10.1038/srep19755 
12. Stellari FF, Lavrentiadou S, Ruscitti F, Jacca S, Franceschi V, Civelli M, et al. 
Enlightened Mannhemia haemolytica lung inflammation in bovinized mice. 
Vet Res (2014) 45:8. doi:10.1186/1297-9716-45-8 
13. Stellari F, Bergamini G, Ruscitti F, Sandri A, Ravanetti F, Donofrio G, et al. 
In vivo monitoring of lung inflammation in CFTR-deficient mice. J Transl 
Med (2016) 14(1):226. doi:10.1186/s12967-016-0976-8 
14. Stellari FF, Franceschi V, Capocefalo A, Ronchei M, Facchinetti F, Villetti 
G, et  al. In vivo imaging of transiently transgenized mice with a bovine 
interleukin 8 (CXCL8) promoter/luciferase reporter construct. PLoS One 
(2012) 7(6):e39716. doi:10.1371/journal.pone.0039716 
15. Stellari F, Bergamini G, Sandri A, Donofrio G, Sorio C, Ruscitti F, et al. In 
vivo imaging of the lung inflammatory response to Pseudomonas aeruginosa 
and its modulation by azithromycin. J Transl Med (2015) 13:251. doi:10.1186/
s12967-015-0615-9 
16. Ma X, Prakash J, Ruscitti F, Glasl S, Stellari FF, Villetti G, et al. Assessment 
of asthmatic inflammation using hybrid fluorescence molecular tomog-
raphy-x-ray computed tomography. J Biomed Opt (2016) 21(1):15009. 
doi:10.1117/1.JBO.21.1.015009 
17. Hübner RH, Gitter W, El Mokhtari NE, Mathiak M, Both M, Bolte H, et al. 
Standardized quantification of pulmonary fibrosis in histological samples. 
Biotechniques (2008) 44(4):507–11. doi:10.2144/000112729 
18. Redente EF, Jacobsen KM, Solomon JJ, Lara AR, Faubel S, Keith RC, et al. Age 
and sex dimorphisms contribute to the severity of bleomycin-induced lung 
injury and fibrosis. Am J Physiol Lung Cell Mol Physiol (2011) 301(4):L510–8. 
doi:10.1152/ajplung.00122.2011 
19. Tebaldi G, Jacca S, Montanini B, Capra E, Rosamilia A, Sala A, et  al. 
Virus-mediated metalloproteinase 1 induction revealed by transcriptome 
profiling of bovine herpesvirus 4-infected bovine endometrial stromal cells. 
Biol Reprod (2016) 95(1):12. doi:10.1095/biolreprod.116.139097 
20. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing 
and evolving hypotheses about its pathogenesis and implications for 
therapy. Ann Intern Med (2001) 134(2):136–51. doi:10.7326/0003-4819- 
134-2-200101160-00015 
21. Selman M, Pardo A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic 
cross-talk disorder. Respir Res (2002) 3:3. doi:10.1186/rr175 
22. Pardo A, Selman M. Role of matrix metaloproteases in idiopathic pulmo-
nary fibrosis. Fibrogenesis Tissue Repair (2012) 5(Suppl 1):S9. doi:10.1186/ 
1755-1536-5-S1-S9 
23. Herrera I, Cisneros J, Maldonado M, Ramirez R, Ortiz-Quintero B, Anso 
E, et al. Matrix metalloproteinase (MMP)-1 induces lung alveolar epithelial 
cell migration and proliferation, protects from apoptosis, and represses 
mitochondrial oxygen consumption. J Biol Chem (2013) 288(36):25964–75. 
doi:10.1074/jbc.M113.459784 
24. Rajah R, Katz L, Nunn S, Solberg P, Beers T, Cohen P. Insulin-like growth 
factor binding protein (IGFBP) proteases: functional regulators of cell 
growth. Prog Growth Factor Res (1995) 6(2–4):273–84. doi:10.1016/0955- 
2235(95)00012-7 
25. Lemaitre V, D’Armiento J. Matrix metalloproteinases in development and 
disease. Birth Defects Res C Embryo Today (2006) 78(1):1–10. doi:10.1002/
bdrc.20065 
26. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the 
regulation of tissue remodelling. Nat Rev Mol Cell Biol (2007) 8(3):221–33. 
doi:10.1038/nrm2125 
27. Hatfield KJ, Reikvam H, Bruserud O. The crosstalk between the matrix 
metalloprotease system and the chemokine network in acute myeloid 
leukemia. Curr Med Chem (2010) 17(36):4448–61. doi:10.2174/09298671079 
4183033 
28. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson 
AH, et al. Processing of tumour necrosis factor-alpha precursor by metallo-
proteinases. Nature (1994) 370(6490):555–7. doi:10.1038/370555a0 
29. Imai K, Dalal SS, Chen ES, Downey R, Schulman LL, Ginsburg M, et  al. 
Human collagenase (matrix metalloproteinase-1) expression in the lungs 
of patients with emphysema. Am J Respir Crit Care Med (2001) 163 
(3 Pt 1):786–91. doi:10.1164/ajrccm.163.3.2001073 
30. McColgan P, Sharma P. Polymorphisms of matrix metalloproteinases 1, 2, 3 
and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 
subjects. Int J Cancer (2009) 125(6):1473–8. doi:10.1002/ijc.24441 
31. Balbin M, Fueyo A, Knauper V, Lopez JM, Alvarez J, Sanchez LM, et  al. 
Identification and enzymatic characterization of two diverging murine 
counterparts of human interstitial collagenase (MMP-1) expressed at sites 
of embryo implantation. J Biol Chem (2001) 276(13):10253–62. doi:10.1074/
jbc.M009586200 
FigUre s1 | effect of intratracheally administration of bleomycin on mice 
body weight. Nine animals were used for each time point, and each time point 
was repeated three times. The data represent the mean ± SEM of a total of 27 
animals. Changes were compared to the vehicle group using ANOVA followed by 
Dunnett’s test. *p < 0.05; **p < 0.01.
FigUre s2 | In vivo (a,B) representative images of sTaT-1-luc transiently 
transgenized mice treated with saline (a) or bleomycin (B) at different time 
posttreatment (7, 14, and 21 days posttreatment). Mice were monitored 
before the treatment to get the baseline and at 4, 24, and 48 h posttreatment by 
in vivo image analysis drawing a region of interest over the chest and using an IVIS 
imaging system (Perkin Elmer Inc., Boston, MA, USA). Light emitted was acquired 
from specific regions by Living Image® software (Perkin Elmer Inc., Boston, MA, 
USA) as photon per second per square centimeter and normalized as FOI respect 
to the saline treated control. (c) Statistical differences were tested by one-way 
ANOVA followed by Dunnett’s post hoc test for group comparisons. Each point 
represents the mean ± SEM of three animals. Changes were compared to the 
vehicle groups using ANOVA followed by Dunnett’s test. *p < 0.05; **p < 0.01.
11
Stellari et al. Real-time Monitoring of Lung Fibrosis
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 199
32. Elkington P, Shiomi T, Breen R, Nuttall RK, Ugarte-Gil CA, Walker 
NF, et  al. MMP-1 drives immunopathology in human tuberculosis 
and transgenic mice. J Clin Invest (2011) 121(5):1827–33. doi:10.1172/ 
JCI45666 
33. Carver PI, Anguiano V, D’Armiento JM, Shiomi T. Mmp1a and Mmp1b 
are not functional orthologs to human MMP1 in cigarette smoke induced 
lung disease. Exp Toxicol Pathol (2015) 67(2):153–9. doi:10.1016/j.etp.2014. 
11.004 
34. Doyle TC, Burns SM, Contag CH. In vivo bioluminescence imaging 
for integrated studies of infection. Cell Microbiol (2004) 6(4):303–17. 
doi:10.1111/j.1462-5822.2004.00378.x 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could 
be construed as a potential conflict of interest.
Copyright © 2017 Stellari, Ruscitti, Pompilio, Ravanetti, Tebaldi, Macchi, Verna, 
Villetti and Donofrio. This is an open-access article distributed under the terms 
of the Creative Commons Attribution License (CC BY). The use, distribution or 
reproduction in other forums is permitted, provided the original author(s) or licensor 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
